(BTH)


NYSE . Currency in USD
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
OpenN/A
Prev CloseN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52wk Rangeundefined - undefined
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
BetaN/A
VolumeN/A
Avg Vol (3m)N/A
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Marketwired5 months ago

    Breathtec Biomedical Provides Update on Lead Project and In-Licensing Discussions

    Breathtec Biomedical Inc. , a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection ...

  • Marketwired6 months ago

    Breathtec Biomedical Appoints Experienced Product Development and Regulatory Consultant

    Breathtec Biomedical Inc. , a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection ...

  • American City Business Journals7 months ago

    The Carlyle Group raises $2.4 billion for new investments

    D.C.-based private equity giant The Carlyle Group (CG) has raised $2.4 billion to purchase stakes in mid-sized companies. The Carlyle Equity Opportunity Fund II will focus on equity investments ranging from $20 million to $200 million and serves as a follow-up to a previous fund, the Carlyle Equity Opportunity Fund I, which raised $1.1 billion in 2011 and invested in 15 companies. The new fund has already made investments in marine transportation company Seacor Holdings Inc. (CKH), merchandising solutions firm Array Canada Inc. and in the McLean-based legal tech company LDiscovery LLC. Rodney Cohen, managing director and co-head of the U.S. middle market investment team, said he was pleased that The Carlyle Group was able to raise more than twice the money than its previous fund.